KINETA Stock Price, News & Analysis

Kineta, Inc. (symbol: KANT) has been described in public disclosures as a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance. The company has traded on the OTC Pink market under the ticker KANT and has positioned its work around next-generation immunotherapies designed to address major challenges with current cancer therapy.

According to multiple press releases, Kineta’s immuno-oncology pipeline has included KVA12123, a VISTA blocking immunotherapy, and a preclinical monoclonal antibody targeting CD27. KVA12123 has been evaluated in the VISTA-101 Phase 1/2 clinical trial in patients with advanced solid tumors, both as a monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). Publicly reported data from this program describe KVA12123 as an anti-VISTA monoclonal antibody that has shown a favorable safety and tolerability profile in early-stage clinical testing, with no dose-limiting toxicities reported at the dose levels described.

VISTA (V-domain Ig suppressor of T cell activation) is characterized in Kineta’s and TuHURA Biosciences’ communications as a negative immune checkpoint that suppresses T cell function in a variety of solid tumors. High VISTA expression in tumors has been associated in those materials with poor survival and a lack of response to other immune checkpoint inhibitors. KVA12123 is described as a VISTA blocking immunotherapy that has demonstrated strong tumor growth inhibition in preclinical models, both as a monotherapy and in combination with other checkpoint inhibitors, and is intended to address immune suppression in the tumor microenvironment.

Public announcements also note that Kineta has leveraged expertise in innate immunity and focused on discovering and developing potentially differentiated immunotherapies. The company’s work on KVA12123 has been highlighted at scientific and medical meetings, including the American Association for Cancer Research (AACR) Annual Meeting and the Society for Immunotherapy of Cancer (SITC) Annual Meeting, where updated clinical data from the VISTA-101 study have been presented.

In February 2024, Kineta disclosed a significant corporate restructuring aimed at substantially reducing expenses and preserving cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new patients in the ongoing VISTA-101 Phase 1/2 clinical trial at that time, while the company explored strategic alternatives. Subsequent disclosures explain that, following an exclusivity and right of first offer agreement with TuHURA Biosciences, Inc., enrollment in VISTA-101 was later reopened in collaboration with TuHURA.

Kineta’s corporate trajectory has been shaped by its relationship with TuHURA Biosciences. On December 12, 2024, TuHURA and Kineta announced a definitive merger agreement under which TuHURA would acquire Kineta, including the rights to KVA12123, for a combination of cash and shares of TuHURA common stock via a merger transaction. Later communications report that stockholders of both companies approved the proposed merger and that TuHURA and Kineta anticipated closing the transaction following satisfaction or waiver of remaining conditions.

A subsequent press release dated June 30, 2025, from TuHURA Biosciences states that TuHURA completed the acquisition of Kineta, Inc. In that announcement, Kineta is referred to as the maker of a novel VISTA inhibiting monoclonal antibody formerly known as KVA12123, which TuHURA renamed TBS-2025. The same release describes how each share of Kineta common stock was converted into the right to receive shares of TuHURA common stock and potential additional consideration, as outlined in the merger agreement.

Following the closing of the acquisition, the VISTA inhibiting antibody originating from Kineta has been integrated into TuHURA’s immuno-oncology pipeline under the designation TBS-2025. TuHURA has publicly discussed plans to investigate this antibody in further clinical development, including a Phase 2 trial in NPM1-mutated acute myeloid leukemia (AML), and has characterized the program as aligned with its focus on overcoming resistance to cancer immunotherapy.

Because Kineta has been acquired by TuHURA Biosciences, the KANT ticker represents a company that has undergone a corporate transformation. Investors researching KANT are often looking at Kineta’s historical activities as a clinical-stage biotechnology company, its VISTA-101 clinical program for KVA12123, and the terms and implications of its merger into TuHURA. For current information on the underlying VISTA antibody program and related development plans, TuHURA’s public disclosures describe the ongoing status of the asset now known as TBS-2025.